Project Grant R21CA286304
Award Date
7/8/24
Completion Date
6/30/26
Dollars Obligated
$828K
Federal Agency
National Cancer Institute
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This federal Project Grant award for $1,108,391.72, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at The Leland Stanford Junior University to define the optimal characteristics of chimeric antigen receptor (CAR) T cells for the treatment of large B-cell lymphoma (LBCL). The key research goals are: (1) to identify the most therapeutically relevant CAR T cell subsets in LBCL patients, and (2) to overcome immune suppression by CAR T...
This $604,627 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Trustees of Dartmouth College to deconvolve the heterogeneity of chimeric antigen receptor (CAR) T cells and engineer durable antitumor immunity. The project aims to understand how individual CAR T cell subsets behave in vivo and develop strategies to program CAR T cells to generate protective memory T cells. Key objectives include using dynamic lineage recording to...
This $1,477,396 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop an innovative approach to enhance the efficacy and durability of CD19-targeted CAR T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The key elements include: Selecting cytomegalovirus (CMV)-specific T cells for modification with a CD19-targeting CAR, and then infusing the resulting bi-specific CMV-CD19 CAR T cells into patients. Inducing expansion of the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $402,600.00 to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The research aims to evaluate the efficacy and safety of these U5 snRNP-targeted CAR T-cells, investigate the mechanisms underlying the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Yale University will support the development of a mechano-transduction platform to enhance the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The $195,766 award, with a period of performance from December 2024 to November 2026, will fund research to: Use force sensors to measure forces along key immune receptors, and Engineer force transduction...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,271,780.00 to the University of Pittsburgh to develop small molecule adaptors for reprogramming universal chimeric antigen receptor (CAR) T cell therapies. The key objectives are: Develop small molecule adaptors to target universal CAR T cells to multiple antigens, including simultaneous targeting of tumor cells and immunosuppressive cells. Enhance CAR T cell targeting specificity...
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research (CFDA 93.396) program provides $587,108 to The Trustees of the University of Pennsylvania to conduct research aimed at enhancing the efficacy and durability of chimeric antigen receptor (CAR) T cell immunotherapy for cancer treatment. The key objectives are to improve the transduction efficiency and functional characteristics of non-activated CAR T cells by modulating the type I interferon (IFN1) signaling...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Luminary Therapeutics, Inc., a self-certified small disadvantaged business, to develop an innovative chimeric antigen receptor (CAR) T-cell therapy targeting epithelial ovarian carcinoma. The $798,512 award, with a project period from September 2024 to August 2025, supports the development of an "armored split CAR" T-cell product that combines two CAR molecules...
This $107,948 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will fund the development of tunable, microenvironment-responsive CAR T cells to enhance the potency and safety of solid tumor CAR T cell therapy, with a focus on ovarian cancer. The research aims to engineer a hypoxia biosensor circuit in primary human T cells to enable targeted CAR expression and cytokine delivery within the tumor microenvironment, thereby improving anti-tumor efficacy...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research conducted by the Sloan-Kettering Institute for Cancer Research to develop and translate chimeric antigen receptor (CAR) T-cell therapies for solid tumors. The $1,313,806 award, granted on August 13, 2024, aims to further advance Sloan-Kettering's work on MSLN-targeted CAR T-cell therapies, including exploring mechanisms to enhance cytotoxicity against low-antigen...